Enlivex: Surges on positive early data from experimental COVID-19 therapy study

Enlivex

03/12/2020 14:30

** U.S.-listed shares of Israel-based drug developer
 ENLV.O  surge 35.8% to $11.23 premarket - a near one-month high
    ** ENLV reports positive early results from its mid-stage
study testing its experimental therapy Allocetra in severe and
critical COVID-19 patients  urn:newsml:reuters.com:*:nGNX5frhsF
    ** Co says all 7 patients treated Allocetra until a certain
date recovered completely and were discharged from hospital an
avg. of 4.7 days after treatment
    ** Co says therapy was well tolerated with no serious
adverse events
    ** Allocetra is also being tested to treat patients with
organ failure associated with sepsis
    ** Up to Wednesday's close, stock down 1.5% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))